Lot certificates published
Plain, secure packaging
Catalog/ARA-290 (Cibinetide)
ARA-290 (Cibinetide)
#1044
Lyophilized Peptide

ARA-290 (Cibinetide) 10mg

ARA-290 (cibinetide) is a synthetic 11-amino-acid peptide corresponding to the helix-B surface region of erythropoietin (EPO), bearing an N-terminal pyroglutamate. The pyroglutamate is definitional rather than incidental: the free-glutamine parent peptide (HBSP, CAS 924902-90-9) is a separate compound, and cibinetide / CAS 1208243-50-8 denotes specifically the cyclized pyroglutamate form (pHBSP). It is a non-erythropoietic, non-hematopoietic EPO derivative that is reported to act through the proposed innate repair receptor (IRR), a heteromeric EPO-receptor / β-common-receptor (EPOR-βcR) complex whose structure has not been confirmed, without stimulating erythropoiesis, making it a tool for isolating the tissue-protective arm of EPO signaling. Supplied strictly for in-vitro research and laboratory use only. Not for human or animal use.

Select Option

Single (10mg)$54.99

2+ save 5% · 5+ save 10% · 10+ save 20%

Quantity

1
= $54.99
Buy now

Mechanism of Action

ARA-290 is reported to activate the proposed innate repair receptor (EPOR-βcR complex) expressed in response to injury and metabolic stress, without binding the homodimeric EPO receptor that drives red-cell production. IRR activation engages pro-survival signaling (Akt, eNOS), modulates VEGF, and attenuates pro-inflammatory cytokine expression (IL-1β, TNF-α) in preclinical injury models, dissociating tissue-protective signaling from the erythropoietic effects of native EPO.

Properties

CAS Number

1208243-50-8

Molecular Formula

C₅₁H₈₄N₁₆O₂₁

Molecular Weight

1257.32 Da

Sequence

pGlu-Glu-Gln-Leu-Glu-Arg-Ala-Leu-Asn-Ser-Ser

Half-Life

~2 min (rat and rabbit plasma)

Storage

Store lyophilized at -20°C. Reconstituted at 2-8°C, use within 14 days.

Shipping & Delivery

  • Same-day dispatch on orders placed before 2 PM MST (Arizona — no daylight saving).
  • US shipping from $5. Free Priority on orders $100+ (before discounts).
  • Plain, unmarked packaging — no branding or product names on the outside.
  • Ships to all 50 states, DC, Puerto Rico & the U.S. Virgin Islands; tracking emailed on every order.
Full shipping details

Quality & Testing

  • No third-party certificate has been published for this compound yet.
  • USA-based; dispatched from Phoenix, Arizona.
  • Supplied strictly for in-vitro laboratory research — not for human use.

Certificates are published for each lot we have tested — see the 14 published so far.

Research Applications

1Innate repair receptor (EPOR-βcR) signaling studies
2Non-erythropoietic EPO derivative pharmacology
3Anti-inflammatory and tissue-protection injury models
4Akt/eNOS pro-survival pathway research
5Neuropathic and ischemic tissue models

References & Citations

(4)
1

Nonerythropoietic, tissue-protective peptides derived from the tertiary structure of erythropoietin.

Brines M, Patel NS, Villa P, Brines C, Mennini T, De Paola M, Erbayraktar Z, Erbayraktar S, Sepodes B, Thiemermann C, Ghezzi P, Yamin M, Hand CC, Xie QW, Coleman T, Cerami A

Proc Natl Acad Sci U S A (2008)PMID: 18676614 DOI
2

Activation of the EPOR-β common receptor complex by cibinetide ameliorates impaired wound healing in mice with genetic diabetes

Bitto A, Irrera N, Pizzino G, et al.

Biochim Biophys Acta Mol Basis Dis (2017)PMID: 29223734 DOI
3

The vasoreparative potential of endothelial colony-forming cells in the ischemic retina is enhanced by cibinetide, a non-hematopoietic erythropoietin mimetic

O'Leary OE, Canning P, Reid E, et al.

Exp Eye Res (2019)PMID: 30876881 DOI
4

Improvement of Islet Allograft Function Using Cibinetide, an Innate Repair Receptor Ligand

Yao M, Watanabe M, Sun S, et al.

Transplantation (2020)PMID: 32345869 DOI

Research Use Only

This product is intended strictly for in-vitro research, educational, and laboratory use. Not for human consumption. The information provided is based on published research and does not constitute medical advice.

Research reference

A published identity, mechanism, and bibliography record corresponds to this catalog entry.

Research reference: ARA-290

More references from the Research Library (4)

Further papers cited in the Library's ARA-290 record, each checked against PubMed. They describe the compound in research settings and are not statements about this product. See the full record for its identity, structure and complete bibliography.

  1. Cibinetide dampens innate immune cell functions thus ameliorating the course of experimental colitis.

    Nairz M, Haschka D, Dichtl S, et al.

    Scientific reports (2017)In vitro · AnimalPMID 29026145
  2. Renoprotection and Mechanisms of Erythropoietin and Its Derivatives Helix B Surface Peptide in Kidney Injuries.

    Zhang Y, Chen W, Wu Y, et al.

    Current protein & peptide science (2017)Review articlePMID 27634442
  3. ARA290, a peptide derived from the tertiary structure of erythropoietin, produces long-term relief of neuropathic pain: an experimental study in rats and β-common receptor knockout mice.

    Swartjes M, Morariu A, Niesters M, et al.

    Anesthesiology (2011)AnimalPMID 21873879
  4. EPO does not promote interaction between the erythropoietin and beta-common receptors.

    Cheung Tung Shing KS, Broughton SE, Nero TL, et al.

    Scientific reports (2018)In vitro · AnimalPMID 30127368